Creative approaches that can be used to keep control of oligometastic disease in patients with non-small cell lung cancer were discussed here at the IASLC 19th World Conference on… read more.
WCLC co-Presidents Professor Andrea Bezjak and Dr Natasha Leighl (both of Toronto, Canada) discuss research from their centre on the iimportance of QOL outcome measures in clinical trials.
Patients with unresectable stage III non-small cell lung cancer taking durvalumab had significantly better overall survival than those on placebo after standard chemotherapy and radiation, according to the… read more.
The ALK- and ROS1-inhibitor brigatinib showed a better progression-free survival (PFS) compared to the ALK-inhibitor crizotinib in the first interim analysis of a head-to-head trial in patients with… read more.
The IASLC 19th World Conference on Lung Cancer (WCLC) was full of highlights, including 3 plenary abstracts being presented in the New England Journal of Medicine and involvement from… read more.
Inflammatory bowel disease can have a detrimental impact of health-related quality of life, and reducing the physical and psychological disease burden is an important therapeutic target. Patient-reported outcomes… read more.
To have a chance of preventing IBD clinicians need to be able to predict who is at risk, based on sensitive and selective risk factors. In a translational… read more.
With permutations of potential front-line treatments for non-small cell lung cancer (NSCLC) seemingly endless, one thing seems certain…
June 2018 saw the launch of our first edition of LungCancer.Med, a new congress news e-journal containing interviews with speakers and delegates as well as articles on the latest hot… read more.
In addition to clinical segmentation of MM patients as young or elderly and fit or frail, genetic factors convey important prognostic information and should be taken into account… read more.
Patients with moderate-to-severe uncontrolled asthma treated with the ezcema drug dupilumab have achieved significantly lower rates of severe asthma exacerbation than those using a placebo. Researchers reported this… read more.
The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
